KCNE3
Ensembl | |||||||||
---|---|---|---|---|---|---|---|---|---|
UniProt | |||||||||
RefSeq (mRNA) |
| ||||||||
RefSeq (protein) |
| ||||||||
Location (UCSC) | Chr 11: 74.45 – 74.47 Mb | Chr 7: 99.83 – 99.83 Mb | |||||||
PubMed search | [3] | [4] |
View/Edit Human | View/Edit Mouse |
Potassium voltage-gated channel, Isk-related family, member 3 (KCNE3), also known as MinK-related peptide 2 (MiRP2) is a protein that in humans is encoded by the KCNE3 gene.[5][6]
Function
Voltage-gated potassium channels (Kv) represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. KCNE3 encodes a member of the five-strong KCNE family of voltage-gated potassium (Kv) channel ancillary or β subunits.
KCNE3 is best known for modulating the KCNQ1 Kv α subunit, but it also regulates hERG, Kv2.1, Kv3.x, Kv4.x and Kv12.2 in heterologous co-expression experiments and/or in vivo.
Co-assembly with KCNE3 converts KCNQ1 from a voltage-dependent delayed rectifier K+ channel to a constitutively open K+ channel with an almost linear current/voltage (I/V) relationship.[7] KCNQ1-KCNE3 channels have been detected in the basolateral membrane of mouse small intestinal crypts, where they provide a driving force to regulate Cl- secretion.[8] Specific amino acids within the transmembrane segment (V72) and extracellular domain (D54 and D55) of KCNE3 are important for its control of KCNQ1 voltage dependence.[9][10] D54 and D55 interact electrostatically with R237 in the S4 segment of the KCNQ1 voltage sensor, helping to stabilize S4 in the activated state, which in turn locks open the channel unless the cell is held at a strongly hyperpolarizing (negative) membrane potential. The ability of KCNQ1-KCNE3 channels to remain open at weakly negative membrane potentials permits their activity in non-excitable, polarized epithelial cells such as those in the intestine.
KCNE3 also interacts with hERG, and when co-expressed in Xenopus laevis oocytes KCNE3 inhibits hERG activity by an unknown mechanism. It is not known whether hERG-KCNE3 complexes occur in vivo.[7]
KCNE3 interacts with Kv2.1 in vitro and forms complexes with it in rat heart and brain. KCNE3 slows Kv2.1 activation and deactivation. KCNE3 can also regulate channels of the Kv3 subfamily, which are best known for permitting ultrarapid firing of neurons because of the extremely fast gating (activation and deactivation). KCNE3 moderately slows Kv3.1 and Kv3.2 activation and deactivation, and moderately speeds their C-type inactivation.[11][12] It is possible that KCNE3 (and KCNE1 and 2) regulation of Kv3.1 and Kv3.2 helps to increase functional diversity within the Kv3 subfamily.[13] KCNE3 also regulates Kv3.4, augments its current by increasing the unitary conductance and by left-shifting the voltage dependence such that the channel can open at more negative voltages. This may allow Kv3.4-KCNE3 channels to contribute to setting resting membrane potential.[14]
KCNE3 inhibits the fast inactivating Kv channel Kv4.3, which generates the transient outward Kv current (Ito) in human cardiac myocytes.[15] similarly, KCNE3 was recently found to inhibit Kv4.2, and it is thought that this regulation modulates spike frequency and other electrical properties of auditory neurons.[16]
Kv12.2 channels were found to be inhibited by endogenous KCNE3 (and KCNE1) subunits in Xenopus laevis oocytes. Thus, silencing of endogenous KCNE3 or KCNE1 using siRNA increases the macroscopic current of exogenously expressed Kv12.2. Kv12.2 forms a tripartite complex with KCNE1 and KCNE3 in oocytes, and may do so in mouse brain.[17] Previously, endogenous oocyte KCNE3 and KCNE1 were also found to inhibit exogenous hERG activity and slow the gating of exogenous Kv2.1.[18][19]
Structure
KCNE proteins are type I membrane proteins, and each assembles with one or more types of Kv channel α subunit to modulate their gating kinetics and other functional parameters. KCNE3 has a larger predicted extracellular domain, and smaller predicted intracellular domain, in terms of primary structure, when compared to other KCNE proteins.[20] As with other KCNE proteins, the transmembrane segment of KCNE3 is thought to be α-helical, and the extracellular domain also adopts a partly helical structure.[21] KCNE3, like KCNE1 and possibly other KCNE proteins, are thought to make contact with the S4 of one α subunit and the S6 of another α subunit within the tetramer of Kv α subunits in a complex. No studies have as yet reported the number of KCNE3 subunits within a functional channel complex; it is likely to be either 2 or 4.
Tissue distribution
KCNE3 is most prominently expressed in the colon, small intestine, and specific cell types in the stomach.[22] It is also detectable in the kidney and trachea, and depending on the species is also reportedly expressed at lower levels in the brain, heart and skeletal muscle. Specifically, KCNE3 was detected in rat, horse and human heart,[12][23][24] but not in mouse heart.[8][25] Some have observed KCNE3 expression in rat brain, rat and human skeletal muscle, and the mouse C2C12 skeletal muscle cell line, others have not detected it in these tissues in the mouse.[8][11][14][26]
Clinical significance
Genetic disruption of the Kcne3 gene in mice impairs intestinal cyclic AMP-stimulated chloride secretion via disruption of intestinal KCNQ1-KCNE3 channels that are important for regulating the chloride current. KCNE3 also performs a similar function in mouse tracheal epithelium. Kcne3 deletion in mice also predisposes to ventricular arrhythmogenesis, but KCNE3 expression is not detectable in mouse heart. The mechanism for ventricular arrhythmogenesis was demonstrated to be indirect, and associated with autoimmune attack of the adrenal gland and secondary hyperaldosteronism (KCNE3 is not detectable in the adrenal gland). The elevated serum aldosterone predisposes to arrhythmias triggered in a coronary artery ligation ischemia/reperfusion injury model. Blockade of the aldosterone receptor with spironolactone removed the ventricular arrhythmia predisposition in Kcne3-/- mice. Kcne3 deletion also impairs auditory function because of the loss of regulation of Kv4.2 channels by KCNE3 in spiral ganglion neurons (SGNs) of the auditory system. KCNE3 is thought to regulate SGN firing properties and membrane potential via its modulation of Kv4.2.[16] While one group reported not observing skeletal muscle abnormalities in Kcne3 null mice,[27] a more comprehensive study showed clear skeletal muscle abnormalities as a result of germline Kcne3 deletion, including abnormal hindlimb clasping, altered contractile response to repetitive stimulation, and transcriptome remodeling.[28]
Mutations in human KCNE3 have been associated with hypokalemic periodic paralysis[14] and Brugada syndrome.[29]
The association with the R83H mutation in KCNE3 is controversial and other groups have detected the same mutation in individuals not exhibiting symptoms of periodic paralysis.[30] The mutation may instead be a benign polymorphism, or else it requires another genetic or environmental 'hit' before it becomes pathogenic, although the importance of KCNE3 in skeletal muscle function is supported by transgenic mouse studies.[28] Kv channels formed by Kv3.4 and R83H-KCNE3 have impaired function compared to wild-type channels, are less able to open at negative potentials and are sensitive to proton block during acidosis.[31][14]
KCNE3-linked Brugada syndrome is thought to arise because of mutant KCNE3 being unable to inhibit Kv4.3 channels in ventricular myocytes as it is suggested to do in healthy individuals. It appears that, unlike in mice, KCNE3 expression is detectable in human heart. It has not been reported whether people with KCNE3 mutations also have adrenal gland-related symptoms such as hyperaldosteronism.
KCNE3 mutations have been suggested to associate with Ménière's disease in Japanese, a condition that presents as tinnitus, spontaneous vertigo, and periodic hearing loss,[32] however this association is also controversial and was not observed in a Caucasian population.[33] In a study of tinnitus utilizing deep resequencing analysis, the authors were not able to prove or disprove association of KCNE3 sequence variation with tinnitus.[34]
See also
Notes
Wikidata Q37028794 . |
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000175538 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000035165 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Entrez Gene: KCNE3 potassium voltage-gated channel, Isk-related family, member 3".
- S2CID 8507168.
- ^ S2CID 205004809.
- ^ PMID 20051516.
- PMID 11994278.
- PMID 20040519.
- ^ PMID 12954870.
- ^ PMID 19219384.
- PMID 14679187.
- ^ S2CID 16809594.
- PMID 16782062.
- ^ PMID 24727472.
- PMID 19623261.
- PMID 12529362.
- PMID 16326911.
- S2CID 8507168.
- PMID 20044833.
- PMID 11527966.
- PMID 12063283.
- PMID 19122847.
- PMID 24225147.
- S2CID 7159171.
- PMID 20051516.
- ^ PMID 28356343.
- PMID 19122847.
- S2CID 15449273.
- S2CID 21538479.
- S2CID 11258678.
- S2CID 25363712.
- PMID 21899751.
Further reading
- Bonaldo MF, Lennon G, Soares MB (Sep 1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Research. 6 (9): 791–806. PMID 8889548.
- Melman YF, Domènech A, de la Luna S, McDonald TV (Mar 2001). "Structural determinants of KvLQT1 control by the KCNE family of proteins". The Journal of Biological Chemistry. 276 (9): 6439–44. PMID 11104781.
- Dedek K, Waldegger S (Sep 2001). "Colocalization of KCNQ1/KCNE channel subunits in the mouse gastrointestinal tract". Pflügers Archiv. 442 (6): 896–902. S2CID 25496942.
- Abbott GW, Goldstein SA (Mar 2002). "Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism". FASEB Journal. 16 (3): 390–400. S2CID 26205057.
- Mazhari R, Nuss HB, Armoundas AA, Winslow RL, Marbán E (Apr 2002). "Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval". The Journal of Clinical Investigation. 109 (8): 1083–90. PMID 11956246.
- Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM (Nov 2002). "A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis". The Journal of Clinical Endocrinology and Metabolism. 87 (11): 4881–4. PMID 12414843.
- Jurkat-Rott K, Lehmann-Horn F (Mar 2004). "Periodic paralysis mutation MiRP2-R83H in controls: Interpretations and general recommendation". Neurology. 62 (6): 1012–5. S2CID 16831070.
- Lundquist AL, Turner CL, Ballester LY, George AL (Jan 2006). "Expression and transcriptional control of human KCNE genes". Genomics. 87 (1): 119–28. PMID 16303284.
- Panaghie G, Tai KK, Abbott GW (Feb 2006). "Interaction of KCNE subunits with the KCNQ1 K+ channel pore". The Journal of Physiology. 570 (Pt 3): 455–67. PMID 16308347.
- Oh JH, Yang JO, Hahn Y, Kim MR, Byun SS, Jeon YJ, Kim JM, Song KS, Noh SM, Kim S, Yoo HS, Kim YS, Kim NS (Dec 2005). "Transcriptome analysis of human gastric cancer". Mammalian Genome. 16 (12): 942–54. S2CID 69278.
External links
- GeneReviews/NIH/NCBI/UW entry on Brugada syndrome
- KCNE3+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- KCNE3 human gene location in the UCSC Genome Browser.
- KCNE3 human gene details in the UCSC Genome Browser.
- Overview of all the structural information available in the PDB for UniProt: Q9Y6H6 (Potassium voltage-gated channel subfamily E member 3) at the PDBe-KB.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.